Could Momordica Charantia Be Effective In The Treatment of COVID19?

Burak Tüzün; Koray Sayin; Hilmi Ataseven

doi:10.17776/csj.1009906

EN

Could Momordica Charantia Be Effective In The Treatment of COVID19?

Abstract

One of the deadliest diseases is the SARS-CoV-2 virus, today. The rate of spread of this virus is very high. Momordica Charantia extracts studied for this virus. The inhibitory activities of 96 components in the extract of Momordica Charantia were compared against the SARS-CoV-2 virus. Molecular docking method was initially used for this comparison. ADME/T analysis of the inhibitors with the highest inhibitory activity was performed using the results obtained from these calculations. The molecular docking calculations of the molecule with the highest inhibitory activity were tried to be supported by MM-PBSA calculations. The molecular mechanics Poisson-Boltzmann surface binding free energy values of area (MM-PBSA) calculations study interactions between inhibitor molecules and SARS-CoV-2 virus proteins at 100 ps. Finally, the molecules with the highest inhibitory activity were compared with FDA approved drugs. As a result of the made molecular docking calculations, the docking score parameter is Karaviloside III with -9.36, among the extracts of momordica charantia, which has the most negative value. The Gibbs free energy value of the Karaviloside III against 6X6P protein with the best docking score value was calculated. This value is -477143.61±476.53. As a result of the comparison of inhibitory activities of extracts of Momordica charantia against SARS-CoV-2 virus, it has been observed that the Karaviloside III molecule has higher inhibitory activity than other melodies and FDA drugs.

Keywords

SARS-CoV-2, Molecular docking, COVID-19, Momordica charantia, ADME/T .

Supporting Institution

sivas cumhuriyet üniversite

Project Number

rgd-020

Thanks

This work is supported by the Scientific Research Project Fund of Sivas Cumhuriyet University under the project number RGD-020. This research was made possible by TUBITAK ULAKBIM, High Performance, and Grid Computing Center (TR-Grid e-Infrastructure).

References

[1] Gorbalenya A.E., Baker S.C., Baric R., Groot R.J.D., Drosten C., Gulyaeva A.A., ... Ziebuhr J., Severe acute respiratory syndrome-related coronavirus: Classifying 2019-NCoV and naming it SARS-CoV-2, Nature Microbiology, (2020) 1–9.
[2] Alagaili A.N., Briese T., Mishra N., Kapoor V., Sameroff S.C., de Wit E., ... Lipkin W.I., Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia, MBio, 5(2) (2014) e00884-14.
[3] Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., ... Zhang L., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, The Lancet, 395(10223) (2020) 507-513.
[4] Ahmed F.S., Quadeer A.A., McKay R.M., Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies, Viruses, 12(3) (2020) 254.
[5] Tao Y., Shi M., Chommanard C., Queen K., Zhang J., Markotter W., ... Tong S., Surveillance of bat coronaviruses in Kenya identifies relatives of human coronaviruses NL63 and 229E and their recombination history, Journal of Virology, 91(5) (2017) e01953–16.
[6] Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., ... Peng Z., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA, 323(11) (2020) e201585.
[7] Wang M., Cao R., Zhang L., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res., 30(3) (2020) 269-271.
[8] Gallagher T.M., Buchmeier M.J., Coronavirus spike proteins in viral entry and pathogenesis, Virology, 279(2) (2001) 371–374.
[9] Ahn D.G., Shin H.J., Kim M.H., Lee S., Kim H.S., Myoung J., ... Kim S.J., Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19), Journal of Microbiology and Biotechnology, 30(3) (2020) 313–324.
[10] Schoeman D., Fielding B.C., Coronavirus envelope protein: Current knowledge, Virology Journal, 16(1) (2019) 69.

[11] Sheahan T.P., Sims A.C., Leist S.R., Schäfer A., Won J., Brown A.J., ... Baric R.S. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV Nat., Commun., 11(1) (2020) 1-14.
[12] Maxmen A., More than 80 clinical trials launch to test coronavirus treatments, Nature, 578(7795) (2020) 347−348.
[13] Arabi Y.M., Shalhoub S., Mandourah Y., Al-Hameed F., Al-Omari A., Al Qasim E., ... Fowler R., Ribavirin and Interferon Therapy for Critically Ill Patients with Middle East Respiratory Syndrome: A Multicenter Observational Study, Clin. Infect. Dis., 70(9) (2019) 1837-1844.
[14] Lakhrissi Y., Rbaa M., Tuzun B., Hichar A., Ounine K., Almalki F., Lakhrissi B., Synthesis, structural confirmation, antibacterial properties and bio-informatics computational analyses of new pyrrole based on 8-hydroxyquinoline, Journal of Molecular Structure, 1259 (2022) 132683.
[15] Al-Janabi I.A.S., Yavuz S.Ç., Köprü S., Tapera M., Kekeçmuhammed H., Akkoç S., ... Sarıpınar, E. Antiproliferative activity and molecular docking studies of new 4-oxothiazolidin-5-ylidene acetate derivatives containing guanylhydrazone moiety, Journal of Molecular Structure, 1258 (2022) 132627.
[16] Ahamad J., Amin S., Mir S.R., Momordica charantia Linn.(Cucurbitaceae): Review on phytochemistry and pharmacology, Phytochemistry, 11(2) (2017) 53-65.
[17] Jiratchariyakul W., Wiwat C., Vongsakul M., Somanabandhu A., Leelamanit W., Fujii I., ... Ebizuka Y., HIV inhibitor from Thai bitter gourd, Planta Medica, 67(04) (2001) 350-353.
[18] Nerurkar P., Ray R.B. Bitter melon: antagonist to cancer, Pharmaceutical Research, 27(6) (2010) 1049-1053.
[19] Pitchakarn P., Ogawa K., Suzuki S., Takahashi S., Asamoto M., Chewonarin T., Shirai T., Momordica charantia leaf extract suppresses rat prostate cancer progression in vitro and in vivo, Cancer Science, 101(10) (2010) 2234-2240.
[20] Frisch M.J., Trucks G.W., Schlegel H.B., Scuseria G.E., Robb M.A., Cheeseman J.R., Scalmani G., Barone V., Mennucci B., Petersson G.A., Nakatsuji H., Caricato M., Li X., Hratchian H.P., Izmaylov A.F., Bloino J., Zheng G., Sonnenberg J.L., Hada M., Ehara M., Toyota K., Fukuda R., Hasegawa J., Ishida M., Nakajima T., Honda Y., Kitao O., Nakai H., Vreven T., Montgomery J.A., Peralta J.E., Ogliaro F., Bearpark M., Heyd J.J., Brothers E., Kudin K.N., Staroverov V.N., Kobayashi R., Normand J., Raghavachari K., Rendell A., Burant J.C., Iyengar S.S., Tomasi J., Cossi M., Rega N., Millam J.M., Klene M., Knox J.E., Cross J.B., Bakken V., Adamo C., Jaramillo J., Gomperts R., Stratmann R.E., Yazyev O., Austin A.J., Cammi R., Pomelli C., Ochterski J.W., Martin R.L., Morokuma K., Zakrzewski V.G., Voth G.A., Salvador P., Dannenberg J.J., Dapprich S., Daniels A.D., Farkas O., Foresman J.B., Ortiz J.V., Cioslowski J.,Fox D.J. (2009) Gaussian 09, revision D.01. Gaussian Inc, Wallingford CT.
[21] Schrodinger L. (2019). Small-Molecule Drug Discovery Suite 2019-4.
[22] Schrödinger Release (2019) 2019-4: Protein Preparation Wizard; Epik, Schrödinger, LLC, New York, NY, 2016; Impact, Schrödinger, LLC, New York, NY, 2016; Prime, Schrödinger, LLC, New York, NY,.
[23] Rbaa M., Haida S., Tuzun B., El Hassane A., Kribii A., Lakhrissi Y., ... Berdimurodov E., Synthesis, characterization and bioactivity of novel 8-hydroxyquinoline derivatives: Experimental, molecular docking, DFT and POM analyses, Journal of Molecular Structure, 1258 (2022) 132688.
[24] Schrödinger Release (2019) 2019-4: LigPrep, Schrödinger, LLC, New York, NY, 2019.
[25] Kökbudak Z., Akkoç S., Karataş H., Tüzün B., Aslan G. In Silico and In Vitro Antiproliferative Activity Assessment of New Schiff Bases, Chemistry Select, 7(3) (2022) e202103679.
[26] Koçyiğit Ü.M., Taslimi P., Tüzün B., Yakan H., Muğlu H., Güzel E., 1, 2, 3-Triazole substituted phthalocyanine metal complexes as potential inhibitors for anticholinesterase and antidiabetic enzymes with molecular docking studies, Journal of Biomolecular Structure and Dynamics, (2020) 1-11.
[27] Schrödinger Release 2020-1: QikProp, Schrödinger, LLC, New York, NY, 2020.
[28] Nelson M.T., Humphrey W., Gursoy A., Dalke A., Kalé L.V., Skeel R.D., Schulten K., NAMD: A parallel, object-oriented molecular dynamics program, The International Journal of Supercomputer Applications and High-Performance Computing, 10(4) (1996) 251–268.
[29] Humphrey W., Dalke A., Schulten K., VMD: Visual molecular dynamics, Journal of Molecular Graphics, 14(1) (1996) 33–38.
[30] Celebioglu H.U., Erden Y., Hamurcu F., Taslimi P., Şentürk O.S., Özmen, Ü.Ö., ... Gulçin İ., Cytotoxic effects, carbonic anhydrase isoenzymes, α-glycosidase and acetylcholinesterase inhibitory properties, and molecular docking studies of heteroatom-containing sulfonyl hydrazone derivatives, Journal of Biomolecular Structure and Dynamics, (2020) 1-12.
[31] Huseynova A., Kaya R., Taslimi P., Farzaliyev V., Mammadyarova X., Sujayev, A., ... Gulçin İ. Design, synthesis, characterization, biological evaluation, and molecular docking studies of novel 1, 2-aminopropanthiols substituted derivatives as selective carbonic anhydrase, acetylcholinesterase and α-glycosidase enzymes inhibitors, Journal of Biomolecular Structure and Dynamics, (2020) 1-13.
[32] Taslimi P., Erden Y., Mamedov S., Zeynalova L., Ladokhina N., Tas R., ... Gulcin I., The Biological Activities, Molecular Docking Studies, and Anticancer Effects of 1-Arylsuphonylpyrazole Derivatives, Journal of Biomolecular Structure and Dynamics, (2020) 1-20.
[33] Demir Y., Taslimi P., Koçyiğit Ü. M., Akkuş M., Özaslan M. S., Duran H. E., et al., Determination of the inhibition profiles of pyrazolyl–thiazole derivatives against aldose reductase and α‐glycosidase and molecular docking studies, Archiv der Pharmazie, (2020) e2000118.
[34] Lipinski C. A., Lead-and drug-like compounds: the rule-of-five revolution, Drug Discovery Today: Technologies, 1(4) (2004) 337-341.
[35] Lipinski C. A., Lombardo F., Dominy B. W., Feeney P. J., Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Advanced Drug Delivery Reviews, 23 (1997) 3-25.
[36] Jorgensen W.J., Duffy E.M., Prediction of drug solubility from structure, Advanced Drug Delivery Reviews, 54(3) (2002) 355-366.
[37] Kısa D., Korkmaz N., Taslimi P., Tuzun B., Tekin Ş., Karadag A., Şen F., Bioactivity and Molecular Docking Studies of Some Nickel Complexes: New Analogues for the Treatment of Alzheimer, Glaucoma and Epileptic Diseases, Bioorganic Chemistry, (2020) 104066.
[38] Türkan F., Taslimi P., Abdalrazaq S. M., Aras A., Erden Y., Celebioglu H. U., et al., Determination of anticancer properties and inhibitory effects of some metabolic enzymes including acetylcholinesterase, butyrylcholinesterase, alpha glycosidase of some compounds with molecular docking study, Journal of Biomolecular Structure and Dynamics, (2020) 1-17.
[39] Alici E.H., Bilgiçli A.T., Tüzün B., Günsel A., Arabaci G., Yarasir M.N., Alkyl chain modified metalophthalocyanines with enhanced antioxidant-antimicrobial properties by doping Ag+ and Pd2+ ions, Journal of Molecular Structure, 1257 (2022) 132634.
[40] Erdogan M.K., Gundogdu R., Yapar Y., Gecibesler I.H., Kirici M., Behcet L., ... Taslimi P., The Evaluation of Anticancer, Antioxidant, Antidiabetic and Anticholinergic Potentials of Endemic Rhabdosciadium microcalycinum Supported by Molecular Docking Study, ChemistrySelect, 7(17) (2022) e202200400.
[41] Majumdar D., Tüzün B., Pal T.K., Das S., Bankura K., Architectural View of Flexible Aliphatic–OH Group Coordinated Hemi-Directed Pb (II)-Salen Coordination Polymer: Synthesis, Crystal Structure, Spectroscopic Insights, Supramolecular Topographies, and DFT Perspective, Journal of Inorganic and Organometallic Polymers and Materials, (2022) 1-18.
[42] Shafiee S., Davaran S., A mini-review on the current COVID-19 therapeutic strategies, Chemical Review and Letters, 3(1) (2020) 19-22.
[43] Majedi S., Majedi S., Existing drugs as treatment options for COVID-19: A brief survey of some recent results, Journal of Chemistry Letters, 1(1) (2020) 2-8.
[44] Aktaş A., Tüzün B., Aslan R., Sayin K., Ataseven H., New anti-viral drugs for the treatment of COVID-19 instead of favipiravir, Journal of Biomolecular Structure and Dynamics, 39(18) (2021) 7263-7273.
[45] Ataseven H., Sayin K., Tüzün B., Gedikli M., Could boron compounds be effective against SARS-CoV-2?, Bratislava Medical Journal-Bratislavske Lekarske Listy, 122(10) (2021) 753-758.
[46] Tuzun B., Nasibova T., Garaev E., Sayin K., Ataseven H. Could Peganum harmala be effective in the treatment of COVID-19?, Bratislavske Lekarske Listy, 122(9) (2021) 670-679.
[47] Gedikli M.A., Tuzun B., Sayin K., Ataseven H., Determination of inhibitor activity of drugs against the COVID-19, Bratislavske Lekarske Listy, 122(7) (2021) 497-506.
[48] Cetiner E., Sayin K., Tuzun B., Ataseven H., Could boron-containing compounds (BCCs) be effective against SARS-CoV-2 as anti-viral agent?, Bratislavske Lekarske Listy, 122(4) (2021) 263-269.
[49] Gedikli M., Tuzun, B., Aktas A., Sayin K., Ataseven H., Are clarithromycin, azithromycin and their analogues effective in the treatment of COVID19, Bratislava Medical Journal-Bratislavske Lekarske Listy, 122(2) (2021) 101-110.

Details

Primary Language

English

Subjects

-

Journal Section

Research Article

Authors

Burak Tüzün ^*
0000-0002-0420-2043
Türkiye

Koray Sayin
0000-0001-6648-5010
Türkiye

Hilmi Ataseven
Türkiye

Publication Date

June 29, 2022

Submission Date

October 19, 2021

Acceptance Date

May 22, 2022

Published in Issue

Year 2022 Volume: 43 Number: 2

DOI

https://doi.org/10.17776/csj.1009906

IZ

https://izlik.org/JA65WT84NK

APA

Tüzün, B., Sayin, K., & Ataseven, H. (2022). Could Momordica Charantia Be Effective In The Treatment of COVID19? Cumhuriyet Science Journal, 43(2), 211-220. https://doi.org/10.17776/csj.1009906

AMA

1.Tüzün B, Sayin K, Ataseven H. Could Momordica Charantia Be Effective In The Treatment of COVID19? CSJ. 2022;43(2):211-220. doi:10.17776/csj.1009906

Chicago

Tüzün, Burak, Koray Sayin, and Hilmi Ataseven. 2022. “Could Momordica Charantia Be Effective In The Treatment of COVID19?”. Cumhuriyet Science Journal 43 (2): 211-20. https://doi.org/10.17776/csj.1009906.

EndNote

Tüzün B, Sayin K, Ataseven H (June 1, 2022) Could Momordica Charantia Be Effective In The Treatment of COVID19? Cumhuriyet Science Journal 43 2 211–220.

IEEE

[1]B. Tüzün, K. Sayin, and H. Ataseven, “Could Momordica Charantia Be Effective In The Treatment of COVID19?”, CSJ, vol. 43, no. 2, pp. 211–220, June 2022, doi: 10.17776/csj.1009906.

ISNAD

Tüzün, Burak - Sayin, Koray - Ataseven, Hilmi. “Could Momordica Charantia Be Effective In The Treatment of COVID19?”. Cumhuriyet Science Journal 43/2 (June 1, 2022): 211-220. https://doi.org/10.17776/csj.1009906.

JAMA

1.Tüzün B, Sayin K, Ataseven H. Could Momordica Charantia Be Effective In The Treatment of COVID19? CSJ. 2022;43:211–220.

MLA

Tüzün, Burak, et al. “Could Momordica Charantia Be Effective In The Treatment of COVID19?”. Cumhuriyet Science Journal, vol. 43, no. 2, June 2022, pp. 211-20, doi:10.17776/csj.1009906.

Vancouver

1.Burak Tüzün, Koray Sayin, Hilmi Ataseven. Could Momordica Charantia Be Effective In The Treatment of COVID19? CSJ. 2022 Jun. 1;43(2):211-20. doi:10.17776/csj.1009906